search
Back to results

Multi-Site, Post-Market Study of the ICONACY I-Hip System

Primary Purpose

Degenerative Joint Disease

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Iconacy Hip System
Sponsored by
Iconacy Orthopedic Implants, LLC.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Degenerative Joint Disease focused on measuring Hip, Arthroplasty, Arthroplasties, Prosthesis, Iconacy, Osteoarthritis, Arthritis, THA, THR, DJD

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A candidate for primary hip replacement on this operative hip.
  • Is 30 to 80 years of age.
  • Has hip joint disease related to one or more of the following:

    • Degenerative joint disease, (including osteoarthritis or post-traumatic arthritis)
    • Avascular Necrosis (AVN).
  • Will be available for evaluation for the duration of the study.
  • Is able and willing to speak and read English, read and sign the informed consent, fill out the WOMAC and Patient Satisfaction questionnaires, and follow all study procedures.

Exclusion Criteria:

  • Is younger than 30 years of age or older than 80 years of age.
  • Has undergone partial hip replacement or previous ORIF (open reduction internal fixation of femur or acetabulum).
  • Has undergone total hip replacement on this hip in the past (no revisions allowed in study).
  • Infection, or history of infection, acute or chronic, in the hip joint, or acute or chronic unresolved systemic infection.
  • Is currently experiencing radicular pain from the spine down operative leg.
  • Has participated in an IDE/IND clinical investigation with an investigational product in the last three months, or is involved in any personal injury litigation, medical-legal or worker's compensation claim.
  • Is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires.
  • Has been diagnosed with fibromyalgia or has a significant neurological or musculoskeletal disorder or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, Charcot disease).
  • Has been diagnosed with Paget's disease or Congenital hip deformity (dysplasia and/or dislocation).
  • Is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.)
  • Is Obese: (Defined for this study as having a BMI>45).
  • Has insufficient bone quality.
  • Has loss of ligamentous structures.
  • Has materials sensitivity.
  • Is currently a prisoner.
  • Is pregnant or lactating.
  • Has a contralateral amputation.
  • Has a medical condition with less than 2 years of life expectancy.

Sites / Locations

  • Baptist Health LouisvilleRecruiting
  • Sts. Mary & Elizabeth Hospital - KentuckyOne HealthRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Iconacy Hip System

Arm Description

Iconacy hip system prosthesis components

Outcomes

Primary Outcome Measures

Radiographic Success as a Measure of Radiolucency and Component Migration
A subject will be considered a failure for Overall Radiographic Success if one or more of the below conditions are met: The subject will be considered a RADIOGRAPHIC FAILURE if: there is a complete radiolucent line> 3mm wide at the bone/cement interface or there is a >5 degree migration (shift) of the component or there is a >5 mm migration (shift) of the component.
Improvement of Harris Hip Score (with Charnley Score and other comorbidities considered)
Patient satisfaction clinical assessment utilizing questionnaire
Clinical assessment of patient satisfaction will be made by utilizing a Patient Satisfaction (PS) questionnaire.

Secondary Outcome Measures

Revision of Implant Prosthesis as a Measure of Efficacy

Full Information

First Posted
April 28, 2014
Last Updated
May 2, 2014
Sponsor
Iconacy Orthopedic Implants, LLC.
search

1. Study Identification

Unique Protocol Identification Number
NCT02131389
Brief Title
Multi-Site, Post-Market Study of the ICONACY I-Hip System
Official Title
Non-Randomized, Multi-Site, Post-Market Study of the ICONACY I-Hip System (Protocol No. PS-1001)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Unknown status
Study Start Date
April 2014 (undefined)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Iconacy Orthopedic Implants, LLC.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the use and efficacy of the I-Hip for primary total hip replacement surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Joint Disease
Keywords
Hip, Arthroplasty, Arthroplasties, Prosthesis, Iconacy, Osteoarthritis, Arthritis, THA, THR, DJD

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Iconacy Hip System
Arm Type
Other
Arm Description
Iconacy hip system prosthesis components
Intervention Type
Device
Intervention Name(s)
Iconacy Hip System
Other Intervention Name(s)
Iconacy I-Hip, I-Hip, iHip
Primary Outcome Measure Information:
Title
Radiographic Success as a Measure of Radiolucency and Component Migration
Description
A subject will be considered a failure for Overall Radiographic Success if one or more of the below conditions are met: The subject will be considered a RADIOGRAPHIC FAILURE if: there is a complete radiolucent line> 3mm wide at the bone/cement interface or there is a >5 degree migration (shift) of the component or there is a >5 mm migration (shift) of the component.
Time Frame
2 years
Title
Improvement of Harris Hip Score (with Charnley Score and other comorbidities considered)
Time Frame
2 years
Title
Patient satisfaction clinical assessment utilizing questionnaire
Description
Clinical assessment of patient satisfaction will be made by utilizing a Patient Satisfaction (PS) questionnaire.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Revision of Implant Prosthesis as a Measure of Efficacy
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A candidate for primary hip replacement on this operative hip. Is 30 to 80 years of age. Has hip joint disease related to one or more of the following: Degenerative joint disease, (including osteoarthritis or post-traumatic arthritis) Avascular Necrosis (AVN). Will be available for evaluation for the duration of the study. Is able and willing to speak and read English, read and sign the informed consent, fill out the WOMAC and Patient Satisfaction questionnaires, and follow all study procedures. Exclusion Criteria: Is younger than 30 years of age or older than 80 years of age. Has undergone partial hip replacement or previous ORIF (open reduction internal fixation of femur or acetabulum). Has undergone total hip replacement on this hip in the past (no revisions allowed in study). Infection, or history of infection, acute or chronic, in the hip joint, or acute or chronic unresolved systemic infection. Is currently experiencing radicular pain from the spine down operative leg. Has participated in an IDE/IND clinical investigation with an investigational product in the last three months, or is involved in any personal injury litigation, medical-legal or worker's compensation claim. Is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires. Has been diagnosed with fibromyalgia or has a significant neurological or musculoskeletal disorder or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, Charcot disease). Has been diagnosed with Paget's disease or Congenital hip deformity (dysplasia and/or dislocation). Is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.) Is Obese: (Defined for this study as having a BMI>45). Has insufficient bone quality. Has loss of ligamentous structures. Has materials sensitivity. Is currently a prisoner. Is pregnant or lactating. Has a contralateral amputation. Has a medical condition with less than 2 years of life expectancy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Donald L Pomeroy, MD
Phone
502-364-9883
Email
arthroplastyfoundation@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jan Empson, RN
Phone
502-364-0902
Ext
113
Email
empsonja@aol.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Donald L Pomeroy, MD
Organizational Affiliation
Pomeroy & Rhoads Orthopaedics, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baptist Health Louisville
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Empson, RN
Phone
502-364-0902
Ext
113
Email
empsonja@aol.com
First Name & Middle Initial & Last Name & Degree
Donald L Pomeroy, MD
Facility Name
Sts. Mary & Elizabeth Hospital - KentuckyOne Health
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Empson, RN
Phone
502-364-0902
Ext
113
Email
empsonja@aol.com
First Name & Middle Initial & Last Name & Degree
Donald L Pomeroy, MD

12. IPD Sharing Statement

Learn more about this trial

Multi-Site, Post-Market Study of the ICONACY I-Hip System

We'll reach out to this number within 24 hrs